Eli Lilly (LLY) stock is in focus as the company launches Employer Connect to improve employee access to its obesity therapy ...

Lilly Employer Connect aims to make obesity treatments more predictable for employers while lowering costs for workers ...

Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.

March 5 (Reuters) - Eli Lilly said on Thursday it has rolled out a platform to help employers connect with organizations ...

Eli Lilly has officially launched Employer Connect, its direct-to-employer platform for its obesity medications, after ...

The new platform lets employers offer GLP-1 drugs like Zepbound at a discounted rate while choosing from a marketplace of administrators.

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Lilly will make its Zepbound KwikPen (tirzepatide) – which delivers four weekly injections in one device – available through the programme at a cost of $449 across all doses for an individual patient, ...

Eli Lilly announced on " Good Morning America " Monday that its GLP-1 weight-loss drug Zepbound will now be available in a ...

Eli Lilly and Co. (LLY) on Monday announced a new version of its blockbuster weight-loss drug Zepbound, available in a ...

Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The ...